Atea Pharmaceuticals (AVIR) Net Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$16.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.98% year-over-year to -$16.4 million; the TTM figure through Mar 2026 stood at -$40.1 million (up 3.47% YoY), while the FY2025 annual figure was $31.0 million, up 139.2% from the prior year.
• Net Cash Flow was -$16.4 million for Q1 2026 at Atea Pharmaceuticals, down from $18.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $82.5 million in Q2 2024 to a low of -$508.1 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$40.3 million across 5 years, with a median of -$10.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 2271.42% in 2022, then soared 428.28% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $11.9 million in 2022, then sank by 50.29% to $5.9 million in 2023, then sank by 668.76% to -$33.8 million in 2024, then surged by 154.4% to $18.4 million in 2025, then plunged by 189.26% to -$16.4 million in 2026.
• The last three Net Cash Flow figures came in at -$16.4 million (Q1 2026), $18.4 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.